159 related articles for article (PubMed ID: 20531312)
1. Landmark approval for Dendreon's cancer vaccine.
DeFrancesco L
Nat Biotechnol; 2010 Jun; 28(6):531-2. PubMed ID: 20531312
[No Abstract] [Full Text] [Related]
2. Cellular immunotherapy licensed for advanced prostate cancer.
Traynor K
Am J Health Syst Pharm; 2010 Jun; 67(11):862. PubMed ID: 20484204
[No Abstract] [Full Text] [Related]
3. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic cancer vaccine survives biotech bust.
Ledford H
Nature; 2015 Mar; 519(7541):17-8. PubMed ID: 25739610
[No Abstract] [Full Text] [Related]
5. Listening to Provenge--what a costly cancer treatment says about future Medicare policy.
Chambers JD; Neumann PJ
N Engl J Med; 2011 May; 364(18):1687-9. PubMed ID: 21470004
[No Abstract] [Full Text] [Related]
6. Abigail Alliance v. Von Eschenbach: restricting access to potentially lifesaving drugs singe 2007.
Goodman AJ
J Contemp Health Law Policy; 2008; 25(1):107-41. PubMed ID: 19137749
[No Abstract] [Full Text] [Related]
7. Sipuleucel-T (Provenge(®))-Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention.
Jarosławski S; Toumi M
BioDrugs; 2015 Oct; 29(5):301-7. PubMed ID: 26403092
[TBL] [Abstract][Full Text] [Related]
8. The role of complement in dendritic cell (DC) control of T-cell subsets.
Levis WR; Martiniuk F
J Drugs Dermatol; 2010 Nov; 9(11):1364-6. PubMed ID: 21061758
[TBL] [Abstract][Full Text] [Related]
9. Approval of provenge seen as first step for cancer treatment vaccines.
Brower V
J Natl Cancer Inst; 2010 Aug; 102(15):1108-10. PubMed ID: 20668267
[No Abstract] [Full Text] [Related]
10. A shot in the arm for cancer vaccines?
Ledford H
Nature; 2010 Apr; 464(7292):1110-1. PubMed ID: 20414279
[No Abstract] [Full Text] [Related]
11. The regulator disapproves.
Nat Biotechnol; 2008 Jan; 26(1):1. PubMed ID: 18182998
[No Abstract] [Full Text] [Related]
12. Fallout from flip-flops.
Froese P
Nat Biotechnol; 2008 Jun; 26(6):614-5. PubMed ID: 18536677
[No Abstract] [Full Text] [Related]
13. Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer.
Madan RA; Gulley JL
Expert Rev Vaccines; 2011 Feb; 10(2):141-50. PubMed ID: 21332262
[TBL] [Abstract][Full Text] [Related]
14. The Provenge decision.
DeVita VT
Nat Clin Pract Oncol; 2007 Jul; 4(7):381. PubMed ID: 17554239
[No Abstract] [Full Text] [Related]
15. An empiric victory.
Nat Biotechnol; 2010 Jun; 28(6):529. PubMed ID: 20531311
[No Abstract] [Full Text] [Related]
16. Dendritic cell vaccine hits FDA roadblock.
Morrow T
Manag Care; 2007 Jun; 16(6):52-3. PubMed ID: 17682740
[No Abstract] [Full Text] [Related]
17. Provenge approval means sensitive coverage decisions.
Silverman E
Manag Care; 2010 Sep; 19(9):31-4. PubMed ID: 20931888
[No Abstract] [Full Text] [Related]
18. Therapy: An immune one-two punch.
Bourzac K
Nature; 2015 Dec; 528(7582):S134-6. PubMed ID: 26672788
[No Abstract] [Full Text] [Related]
19. Business barriers slowing the pace of cancer immunotherapy research and development.
Tuma RS
J Natl Cancer Inst; 2007 Nov; 99(21):1570-3. PubMed ID: 17971521
[No Abstract] [Full Text] [Related]
20. Trouble at the office.
Allison M
Nat Biotechnol; 2008 Sep; 26(9):967-9. PubMed ID: 18779797
[No Abstract] [Full Text] [Related]
[Next] [New Search]
